- Home
- SJT vs MOLN Comparison
SJT vs MOLN Comparison
Compare SJT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SJT | MOLN |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.0M | 157.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SJT | MOLN |
|---|---|---|
| Price | $5.39 | $3.98 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | ★ 193.9K | 3.5K |
| Earning Date | 11-13-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,557.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,000.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.66 | $3.36 |
| 52 Week High | $7.22 | $5.91 |
Technical Indicators
Market Signals| Indicator | SJT | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 37.61 | 55.40 |
| Support Level | $5.42 | $3.98 |
| Resistance Level | $5.63 | $4.40 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 8.89 | 68.12 |
Price Performance
Historical ComparisonAbout SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.